Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 8;26(8):2140.
doi: 10.3390/molecules26082140.

Novel Ring Systems: Spiro[Cycloalkane] Derivatives of Triazolo- and Tetrazolo-Pyridazines

Affiliations

Novel Ring Systems: Spiro[Cycloalkane] Derivatives of Triazolo- and Tetrazolo-Pyridazines

Csilla Sepsey Für et al. Molecules. .

Abstract

In orderto synthesize new pyridazine derivatives anellated with different nitrogen heterocyclic moieties, spiro[cycloalkane]pyridazinones were transformed into the corresponding thioxo derivatives via a reaction with phosphorus pentasulfide. The reaction of the formed 2,3-diazaspiro[5.5] undec-3-ene-1-thiones with hydrazine provided the corresponding 1-hydrazono-2,3-diazaspiro[5.5] undec-3-ene, whose diazotization led to the desired spiro[cyclohexane-1,8'-tetrazolo[1,5-b]pyridazines. The reaction of dihydropyridazinethiones with benzhydrazide afforded the corresponding 7H-spiro[[1,2,4]triazolo[4,3-b]pyridazin-8,1'-cyclohexanes]. As a result of our work, seven new pyridazinethione intermediates were prepared, which served as starting materials for the synthesis of two kinds of new ring systems: tetrazolo-pyridazines and triazolo-pyridazines. The six new annulated derivatives were characterized by physicochemical parameters. The new N-heterocycles are valuable members of the large family of pyridazines.

Keywords: N-heterocycles; diazotization; pyridazine derivatives; tetrazolo-pyridazines; thionation; triazolo-pyridazines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Pyridazine derivatives under clinical development: ensartinib, relugolix, talazoparib, and olaparib.
Scheme 1
Scheme 1
Synthesis of spiro[cycloalkane]pyridazinones (4a–d and 5a,b) [24,25]; (a) 1a,b (1.0 mmol), Friedel–Crafts reaction: AlCl3 (3.0 mmol), ArH derivative (3.0 mmol), 0 °C (30 min) -> room temperature (RT) (24 h); Grignardreaction: Grignard reagent (1.0 mmol), 0 °C (30 min) -> RT (24 h); (b) 2,3 (0.80 mmol), hydrazine hydrate (2.40 mmol), EtOH, reflux, (4 h); (c) 4a–d, 5a,b isolated yields after thin layer chromatography (TLC) purification: 35–97% [24,25].
Scheme 2
Scheme 2
Thionation reaction of the spiro[cycloalkane]pyridazinones (4a–d and 5a,b); (a) 4a–d, 5a,b (1.0 mmol), P2S5 (3.0 mmol), PhMe, reflux, (6–8 h); (b) 6a–d, 7a,b isolated yields after TLC purification: 40–89%.
Scheme 3
Scheme 3
Preparation of 1-(4-methoxyphenyl)-2,3-diazaspiro[5.5]undec-1-ene-4-thione (6e): (a) 1a (1.0 mmol), Friedel–Crafts reaction: AlCl3 (3.0 mmol), anizole (3.0 mmol), 0 °C (30 min) -> RT (24 h); (b) 2a,e (0.80 mmol), hydrazine hydrate (2.40 mmol), EtOH, reflux, (4 h); (c) 2a,e (1.0 mmol), P2S5 (3.0 mmol), PhMe, reflux, (6–8 h); (d) 2e isolated yield after TLC purification: 14%.
Scheme 4
Scheme 4
Synthesis of the hydrazono-pyridazinone (8a–c) and tetrazole derivatives (9a–c) (a) 6a–c (0.40 mmol), hydrazine monohydrate (1.20 mmol), tetrahydrofuran (THF), reflux, (5 h); (b) 8a–c (0.34 mmol), NaNO2 (0.51 mmol), 0.5 N HCl, 5 °C, (2 h); (c) 8a–c isolated yields after TLC purification: 48–61%; (d) 9a–c isolated yields after TLC purification: 45–77%.
Scheme 5
Scheme 5
Reaction of thioxo-derivatives (6a–c) with benzoic acid hydrazide (11) (a) 6a–c (0.73 mmol), 11 (2.20 mmol), n-BuOH, reflux, (84 h); (b) (c) 10a–c isolated yields after TLC purification: 14–42%.

Similar articles

Cited by

References

    1. Wermuth C.G. Are pyridazines privileged structures? Med. Chem. Comm. 2011;2:935–941. doi: 10.1039/C1MD00074H. - DOI
    1. Castle R.N., editor. The Chemistry of Heterocyclic Compounds Pyridazines. Volume 28. Wiley; Hoboken, NJ, USA: 2009.
    1. Heinisch G., Holzer W., Kunz F., Langer T., Lukavsky P., Pechlaner C., Weissenberger H. On the Bioisosteric Potential of Diazines: Diazine Analogues of the Combined Thromboxane A2 Receptor Antagonist and Synthetase Inhibitor Ridogrel. J. Med. Chem. 1996;39:4058–4064. doi: 10.1021/jm960341g. - DOI - PubMed
    1. Asif M. The Pharmacological Importance of Some Diazine Containing Drug Molecules. Sci. Online Pub. Trans. Org. Chem. 2014;1:1–17.
    1. Akhtar W., Shaquiquzzaman M., Akhter M., Verma G., Khan M.F., Alam M.M. The therapeutic journey of pyridazinone. Eur. J. Med. Chem. 2016;123:256–281. doi: 10.1016/j.ejmech.2016.07.061. - DOI - PubMed

LinkOut - more resources